Last Updated: June 17, 2026

SOLTAMOX Drug Patent Profile

Name: SOLTAMOX Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Soltamox, and when can generic versions of Soltamox launch?

Soltamox is a drug marketed by Mayne Pharma Commrcl and is included in one NDA.

The generic ingredient in SOLTAMOX is tamoxifen citrate. There are sixteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the tamoxifen citrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Soltamox

A generic version of SOLTAMOX was approved as tamoxifen citrate by ACTAVIS LABS FL INC on February 20^th, 2003.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for SOLTAMOX?
What are the global sales for SOLTAMOX?
What is Average Wholesale Price for SOLTAMOX?

Summary for SOLTAMOX

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	79
Clinical Trials:	21
Drug Prices:	Drug price information for SOLTAMOX
What excipients (inactive ingredients) are in SOLTAMOX?	SOLTAMOX excipients list
DailyMed Link:	SOLTAMOX at DailyMed

Drug patent expirations by year for SOLTAMOX

Recent Clinical Trials for SOLTAMOX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Eli Lilly and Company	Phase 2
Jose Pablo Leone	Phase 2
Translational Breast Cancer Research Consortium (TBCRC)	Phase 2

See all SOLTAMOX clinical trials

Pharmacology for SOLTAMOX

Drug Class	Estrogen Agonist/Antagonist
Mechanism of Action	Selective Estrogen Receptor Modulators

US Patents and Regulatory Information for SOLTAMOX

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mayne Pharma Commrcl	SOLTAMOX	tamoxifen citrate	SOLUTION;ORAL	021807-001	Oct 29, 2005		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for SOLTAMOX

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Mayne Pharma Commrcl	SOLTAMOX	tamoxifen citrate	SOLUTION;ORAL	021807-001	Oct 29, 2005	6,127,425	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for SOLTAMOX

See the table below for patents covering SOLTAMOX around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
European Patent Office	0893121	Solution liquide de médicament pour administration orale (Oral liquid medicine solution)	⤷ Start Trial
Portugal	893121		⤷ Start Trial
Germany	69804169		⤷ Start Trial
Spain	2174388		⤷ Start Trial
Denmark	0893121		⤷ Start Trial
Austria	214269		⤷ Start Trial
Japan	H1171269	ORAL LIQUID PHARMACEUTICAL PREPARATION	⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.